SWOG clinical trial number
S0313

Evaluation of CHOP Plus Involved Field Radiotherapy followed by Yttrium-90 Ibritumomab Tiuxetan for Stages I, IE and non-bulky Stages II and IIE, CD20 Positive, High-risk Localized, Aggressive Histologies of Non-Hodgkin's Lymphoma, Phase II

Closed
Phase
Accrual
77%
Published
Abbreviated Title
NON-HODGKIN'S: CHOP + IF RT followed by Yttrium-90 Ibritumomab Tiuxetan
Activated
02/01/2004
Closed
12/15/2008
Participants
Limited: Institutions Listed on the Title Page

Research committees

Lymphoma

Treatment

Radiation Therapy Yttrium-90 ibritumomab tiuxetan CHOP

Eligibility Criteria Expand/Collapse

Biopsy proven non-Hodgkin's lymphoma (NHL) aggressive histology of one of the following histological subtypes: diffuse large B-cell (formerly Working Formulation Groups F, G, H), high-grade B-cell, Burkitt's or Burkitt-like; anaplastic large cell or mantle cell; Stage I, IE, non-bulky II or IIE; CD-20 positive; at least one of the following: non-bulky Stage II or non-bulky Stage IIE disease, Age >/=60, Zubrod PS=2, serum LDH > IULN; CT scan of chest and CT scan of abdomen/pelvis; bone marrow aspirate and biopsy; no prior RT or chemo for lymphoma; Zubrod PS 0-2; no medical contraindications; documented pre-registraton RT consult; no known HIV.

Publication Information Expand/Collapse

2022

Extranodal presentation in limited stage DLBCL as a prognostic marker in three SWOG trials S0014, S0313 and S1001 [Letter to Editor]

D Stephens;H Li;L Constine;T Fitzgerald;J Leonard;B Kahl;M LeBlanc;S Smith;JW Friedberg;D Persky Haematologica Nov 1;107(11):2732-2736

PMid: PMID35833300 | PMC number: PMC9614528

2021

Extranodal presentation in limited stage DLBCL as a prognostic marker in three sequential SWOG trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592)

D Stephens;H Li;L Constine;T Fitzgerald;J Leonard;Kahl;J Song;M LeBlanc;S Smith;JW Friedberg;D Persky American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), poster presentation, #1423

2015

Ibritumomab Consolidation After 3 Cycles of CHOP Plus Radiotherapy in High-Risk Limited-Stage Aggressive B-cell Lymphoma: SWOG S0313

D Persky;TP Miller;J Unger;BD Stea;OW Press;LS Constine;K Barton;JW Friedberg;M Leblanc;RI Fisher Blood Jan 8;125(2):236-241

PMid: PMID25395425 | PMC number: PMC4287635

2014

Long term follow up of SWOG S0313: Ibritumomab Tiuxetan consolidation after 3 cycles of CHOP plus radiotherapy for high risk limited stage aggressive B-cell lymphoma (http://www.bloodjournal.org/content/124/21/4414)

DO Persky;TP Miller;JM Unger;CM Spier;S Puvvada;BD Stea;OW Press;LS Constine;KP Barton;M Leblanc;S Smith;RI Fisher;JW Friedberg Blood 124(21):4414; American Society for Hematology (December 6-9, 2014, San Francisco, CA), poster;

2008

Effect of adding ibritumomab tiuxetan (Zevalin) radioimmunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for high risk limited stage aggressive diffuse B-cell lymphoma (Southwest Oncology Group Study 0313)

TP Miller;JM Unger;CM Spier;B Stea;OW Press;M LeBlanc;RI Fisher Blood 112(11):1231, abst. #3598

Other Clinical Trials

SWOG Clinical Trial Number
S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
12%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase